Global Radiodermatitis Market to Reach USD 668.0 Million by 2033, Catalyzed by Rising Incidences of Different Cancers

January 06, 2025 | Healthcare

IMARC Group’s latest report, titled “Radiodermatitis Market Report by Product (Topical, Oral, Dressings), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Region 2025-2033,” finds that the global radiodermatitis market size reached USD 514.8 Million in 2024. Radiodermatitis, also known as radiation dermatitis, is a skin condition that usually occurs as a side effect during cancer treatment or after interventional radiology. It is caused by radiation therapy used for the treatment of patients with cancers of the breast, lungs, skin, neck, head, or perineum region, wherein the skin is part of the target field. It can be treated using various products, such as hydrophilic creams, hydrogel and hydrocolloid dressings, silicone-coated dressings, silver-leaf dressings, oral analgesics, anti-inflammatory agents, topical antibiotics, and corticosteroids. Since it helps minimize discomfort, reduce pain, and prevent interruption in ongoing therapy while enhancing the overall quality of the patient’s life, radiodermatitis treatment has gained immense traction across the globe.

Global Radiodermatitis Market Trends:

The rising incidences of different cancers among the masses owing to unhealthy lifestyles and excessive smoking and alcohol consumption have led to the widespread adoption of radiation therapy as a treatment option. This, coupled with the surging need to manage the adverse side effects of radiation therapy, represents the primary factor driving the market growth. Apart from this, the increasing public and private funding in ongoing research and development (R&D) activities in the field of life sciences are positively influencing the market growth. In addition, numerous governmental and non-governmental organizations are taking favorable initiatives to spread awareness about the available radiodermatitis treatment and management solutions. Along with this, the escalating demand for novel wound care products and the increasing number of clinical trials are contributing to the market growth. Furthermore, several key players are launching innovative product variants to expand their product portfolio and customer base. In line with this, elevating sales of generic drugs via online and offline distribution channels has catalyzed market growth. Other factors, including the expanding geriatric population, improvements in the healthcare infrastructure, easy availability of supportive healthcare reimbursement policies, and rising consumer healthcare spending, are also providing a positive thrust to the market growth. Looking forward, IMARC Group expects the market value to reach USD 668.0 Million by 2033, growing at a CAGR of 2.94% during 2025-2033.

Market Summary:

  • Based on the product, the market has been segregated into topical (corticosteroids, hydrophilic creams, antibiotics, and others), oral, and dressings (hydrogel and hydrocolloid dressings, no sting barrier film, honey-impregnated gauze, silicone-coated dressings, and others).
  • On the basis of the distribution channel, the market has been classified into hospital, retail, and online pharmacies. 
  • Region-wise, the market has been divided into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
  • The competitive landscape of the market has also been examined, with some of the key players being 3M Company, Bausch Health Companies Inc., Bayer AG, BMG PHARMA S.p.A., Charles River Laboratories International Inc., ConvaTec Group plc, Helsinn Healthcare SA, ICON plc, Integra LifeSciences, Mölnlycke Health Care AB, and Stratpharma AG.


Report Scope:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Million USD
Segment Coverage Product, Distribution Channel, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered 3M Company, Bausch Health Companies Inc., Bayer AG, BMG PHARMA S.p.A., Charles River Laboratories International Inc., ConvaTec Group plc, Helsinn Healthcare SA, ICON plc, Integra LifeSciences, Mölnlycke Health Care AB and Stratpharma AG
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N A
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Radiodermatitis Market to Reach USD 668.0 Million by 2033, Catalyzed by Rising Incidences of Different Cancers
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials